# Chlorogenic Acid (5-caffeoylquinic acid; CGA)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/chlorogenic-acid-5-caffeoylquinic-acid-cga
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 1 / 10
**Category:** Compound
**Also Known As:** 5-caffeoylquinic acid, 5-CQA, CGA, 3-caffeoylquinic acid (neochlorogenic acid isomer), plant gold

## Overview

Chlorogenic acid, primarily the 5-caffeoylquinic acid (5-CQA) isomer, exerts antioxidant effects by upregulating superoxide dismutase (SOD), catalase (CAT), and [glutathione](/ingredients/condition/detox) (GSH), while suppressing [inflammatory](/ingredients/condition/inflammation) signaling via NF-κB and MAPK inhibition and Nrf2 activation. Preclinical data demonstrate that 150 μg/mL CGA reduced [lipid peroxidation](/ingredients/condition/antioxidant) marker MDA by 32.4% and increased SOD activity by 68.9% in oxidative stress cell models, with additional antidiabetic potential through glucose and lipid [metabolism](/ingredients/condition/weight-management) modulation.

## Health Benefits

- **Antioxidant Defense**: CGA at 150 μg/mL upregulates SOD by 68.9%, CAT by 45.3%, and GSH by 39.7% in AlCl3-induced oxidative stress models, reducing the [lipid peroxidation](/ingredients/condition/antioxidant) marker MDA by 32.4% through transcriptional regulation of antioxidant enzyme mRNA and protein expression.
- **[Anti-Inflammatory](/ingredients/condition/inflammation) Activity**: CGA inhibits the NF-κB and MAPK signaling cascades, activates the Nrf2 cytoprotective pathway, and suppresses pro-inflammatory mediators including iNOS, nitric oxide, TNF-α, IL-6, and IL-8 in LPS-stimulated macrophages, additionally promoting a shift toward anti-inflammatory M2 macrophage polarization.
- **Blood Glucose and Lipid Regulation**: CGA modulates glucose and lipid metabolism through shikimate pathway enzyme activity and is associated with improved [insulin sensitivity](/ingredients/condition/weight-management) in animal models, making it a candidate antidiabetic phytochemical under active investigation.
- **Antibacterial and Antibiofilm Effects**: CGA disrupts bacterial [energy metabolism](/ingredients/condition/energy) by inhibiting malate dehydrogenase (MDH) and succinate dehydrogenase (SDH) activity—reducing MDH from 0.823 to 0.295 U/mg in Salmonella enteritidis at 1× MIC—and inhibits growth and biofilm formation in Pseudomonas aeruginosa and Staphylococcus aureus at concentrations of 10–30 μg/mL.
- **Antitumor and Apoptotic Effects**: In preclinical breast cancer (4T1) models, CGA induces apoptosis by modulating the p53, Bax, Bcl-2, and caspase-3 axis, while in Caco-2 colon cancer cells it induces S-phase cell cycle arrest, suggesting multi-cancer antiproliferative potential.
- **Organ Protective Properties**: CGA demonstrates [hepatoprotective](/ingredients/condition/detox) and nephroprotective activity in animal models by reducing oxidative tissue damage, with no observed adverse effects in rats at doses up to 1000 mg/kg over three months.
- **Cardiovascular and Metabolic Support**: Through combined antioxidant, anti-inflammatory, and lipid-modulating effects, CGA is associated with reduced [cardiovascular risk](/ingredients/condition/heart-health) markers in preclinical studies, though large human trials confirming these effects are currently limited.

## Mechanism of Action

Chlorogenic acid primarily acts as a direct free-radical scavenger and indirectly as an inducer of endogenous [antioxidant](/ingredients/condition/antioxidant) enzymes (SOD, CAT, GSH peroxidase) through transcriptional upregulation, mediated in part by Nrf2/ARE pathway activation. In inflammatory contexts, CGA suppresses the NF-κB transcription factor and downstream MAPK phosphorylation cascades, reducing expression of [pro-inflammatory cytokine](/ingredients/condition/inflammation)s (TNF-α, IL-6, IL-8) and enzymes (iNOS) in macrophages while promoting M2 polarization. Antitumor activity is driven by p53-dependent upregulation of pro-apoptotic Bax, downregulation of anti-apoptotic Bcl-2, and subsequent activation of caspase-3 executioner proteases, alongside induction of S-phase arrest through cell cycle checkpoint modulation. Antibacterial action involves disruption of the bacterial tricarboxylic acid (TCA) cycle by inhibiting key mitochondrial enzymes MDH and SDH, impairing [energy production](/ingredients/condition/energy) and membrane integrity in gram-negative and gram-positive pathogens.

## Clinical Summary

No large-scale, placebo-controlled randomized clinical trials with defined sample sizes and pre-registered endpoints have been identified for chlorogenic acid as an isolated compound. The most clinically notable human data is a short-term observation linking 2 g/day CGA intake to a 12% rise in plasma homocysteine over seven days, which raises [cardiovascular](/ingredients/condition/heart-health) safety questions at high supplemental doses. Antidiabetic, [antioxidant](/ingredients/condition/antioxidant), and [anti-inflammatory](/ingredients/condition/inflammation) outcomes have been studied extensively in animal models with statistically significant results, but translation to human benefit remains unconfirmed at specific dosages. Confidence in clinical efficacy is currently low-to-moderate, and CGA should be regarded as a promising investigational bioactive compound rather than a clinically established therapeutic agent.

## Nutritional Profile

Chlorogenic acid is not a macronutrient or essential micronutrient but a secondary plant metabolite (polyphenol ester) present in variable concentrations depending on source and processing. In prunes, total CGA plus neochlorogenic acid content reaches 1.3–3.9 g per 100 g fresh weight, with neochlorogenic acid (3-caffeoylquinic acid) constituting a significant co-occurring isomer at 39.8–92.0 mg per 100 g in some reported fractions. Green coffee beans contain the highest known CGA density among common foods, with 5-CQA representing 35–40% of total CGA, 3-CQA at 10–15%, and the remainder comprising di-CQA isomers (3,4-di-CQA and 4-CQA predominating post-roast). Bioavailability is inherently limited by gastric acid instability and intestinal absorption barriers; microbial [metabolism](/ingredients/condition/weight-management) in the colon produces bioactive catechol and hippuric acid metabolites that may contribute to systemic effects, and lipid-based delivery systems improve absorption by approximately 1.29-fold.

## Dosage & Preparation

- **Green Coffee Bean Extract (standardized)**: Typically 45–50% CGA by weight; commercial supplements commonly provide 200–400 mg extract per dose, though no universally accepted human therapeutic dose has been established in RCTs.
- **Raw Dietary Sources**: Prunes contain 1.3–3.9 g CGA per 100 g; apples provide 0.41–1.16 mg/g; green coffee beans are the richest concentrated source with up to 50% of total CGA as 5-CQA.
- **Liposomal Encapsulation**: Soy phosphatidylcholine/cholesterol liposomes at a 6:1 ratio have demonstrated a 1.29-fold improvement in CGA bioavailability versus unencapsulated forms and are preferred for targeted supplementation.
- **Nanoparticle Formulations**: BSA-silver nanoparticle-CGA complexes and polymeric micelles are under investigation for enhanced stability, controlled release, and improved gastrointestinal absorption.
- **Animal Safety Reference Doses**: No adverse effects in rats at 250–1000 mg/kg body weight over 3 months; a single dose of 2 g/kg green coffee extract (50% CGA) was non-toxic in rat models—these are not equivalent to human supplemental doses.
- **Timing**: No established clinical guidance; based on [glucose metabolism](/ingredients/condition/weight-management) research, pre-meal or with-meal dosing is theoretically preferred for glycemic effects.
- **Roasting Consideration**: Roasting coffee significantly degrades CGA content and shifts isomer profiles toward di-CQA forms; green coffee preparations preserve the highest 5-CQA concentrations.

## Safety & Drug Interactions

At typical dietary and low supplemental doses (up to 200–400 mg green coffee extract daily), chlorogenic acid appears well tolerated, with no cytotoxicity observed in bovine cell studies at 10–30 μg/mL and no adverse effects recorded in rats at 250–1000 mg/kg over three months. High intake of 2 g/day of isolated CGA for as few as seven days elevated plasma homocysteine by 12% in a human observation, which is clinically relevant because elevated homocysteine is an independent [cardiovascular risk](/ingredients/condition/heart-health) factor; individuals with pre-existing cardiovascular disease or MTHFR gene variants should use high-dose CGA with caution. No specific drug interactions are formally characterized in the current literature, but given CGA's inhibitory effects on metabolic enzymes and potential influence on glucose regulation, caution is warranted when combining with antidiabetic medications (risk of additive hypoglycemia) or anticoagulants. Safety in pregnancy and lactation has not been studied, and high-dose CGA supplementation should be avoided in these populations; no maximum safe human dose has been established by regulatory agencies.

## Scientific Research

The evidence base for chlorogenic acid is predominantly preclinical, consisting of in vitro cell culture studies and in vivo rodent and pig models, with very few adequately powered human clinical trials reporting specific effect sizes or sample sizes. Quantified outcomes from cell and animal studies are robust in mechanistic scope—including documented enzyme activity changes, cytokine suppression percentages, and tumor apoptosis induction—but these findings cannot be directly extrapolated to human therapeutic doses without confirmatory RCT data. One human observation noted that consuming 2 g/day of CGA or high-CGA black tea (4 g per 4 liters daily) for seven days elevated plasma homocysteine by approximately 11–12%, a clinically relevant safety signal that lacks full characterization due to absent sample size reporting. Overall, the evidence strength for CGA's [antioxidant](/ingredients/condition/antioxidant) and [anti-inflammatory](/ingredients/condition/inflammation) effects in humans remains preliminary-to-moderate, with the antidiabetic and antitumor applications requiring well-designed phase II/III clinical trials before therapeutic claims can be confidently substantiated.

## Historical & Cultural Context

Chlorogenic acid has been coined 'plant gold' in phytochemical literature due to its widespread distribution across medicinally significant dicotyledonous plants, ferns, and traditional Chinese herbs, where it contributes to the bioactivity of preparations long used before its molecular identity was established. Coffee, the richest dietary source, has a documented history of use in East African and Arabian cultures dating to the 9th–15th centuries, and its stimulant and digestive properties were attributed in part to the polyphenol-rich green bean fraction before roasting became standard. In traditional Chinese medicine, herbs now known to be rich in CGA—such as Lonicera japonica (honeysuckle flower) used in formulas for heat-clearing and anti-infective purposes—were applied for fever, [inflammation](/ingredients/condition/inflammation), and infection without knowledge of CGA as the specific active constituent. Modern scientific interest in isolating and standardizing CGA began in earnest in the late 20th century alongside the broader polyphenol research movement, with biosynthetic engineering of CGA content in crop plants now emerging as an agricultural and nutraceutical frontier.

## Synergistic Combinations

Chlorogenic acid demonstrates enhanced bioavailability when co-formulated with soy phosphatidylcholine in a 6:1 lipid-to-CGA ratio, exploiting phospholipid-mediated membrane permeability to improve intestinal absorption by 1.29-fold—a principle applicable to other polyphenols in the same liposomal stack. CGA combined with other Nrf2-activating compounds such as quercetin or resveratrol may produce additive [antioxidant](/ingredients/condition/antioxidant) and [anti-inflammatory](/ingredients/condition/inflammation) effects through complementary pathway engagement (Nrf2/ARE, NF-κB suppression), though direct combination studies in humans are lacking. In the context of [blood glucose](/ingredients/condition/weight-management) management, CGA may act synergistically with berberine or alpha-lipoic acid, as both compounds modulate glucose uptake and insulin signaling through partially overlapping but distinct mechanisms (AMPK activation, [mitochondrial function](/ingredients/condition/energy)), creating a rationale for combined metabolic support formulations.

## Frequently Asked Questions

### What is chlorogenic acid and what foods contain it?

Chlorogenic acid (CGA) is a polyphenol ester of caffeic acid and quinic acid synthesized naturally in plants via the shikimate pathway. The richest dietary sources are green coffee beans (where 5-CQA can represent up to 50% of total CGA), prunes (1.3–3.9 g per 100 g), apples (0.41–1.16 mg/g), and artichokes; roasting coffee significantly degrades CGA content, making green coffee extracts the most potent concentrated source.

### Does chlorogenic acid help with blood sugar and diabetes?

Preclinical studies in animal models show CGA modulates glucose and lipid metabolism through shikimate pathway enzyme activity and may improve insulin sensitivity, supporting its classification as an antidiabetic candidate compound. However, large-scale human clinical trials with defined endpoints and sample sizes have not yet confirmed a specific therapeutic dose or effect size in people with type 2 diabetes, so it should not currently replace established antidiabetic medications.

### What is the recommended dosage of chlorogenic acid supplements?

No universally accepted human therapeutic dose for isolated chlorogenic acid has been established through clinical trials. Commercial green coffee bean extracts standardized to 45–50% CGA are commonly sold at 200–400 mg extract per dose; rat toxicity studies show no adverse effects up to 1000 mg/kg body weight over three months, but high human intake of 2 g/day CGA has been associated with a 12% rise in plasma homocysteine within seven days, suggesting caution at elevated doses.

### Are there any side effects or drug interactions with chlorogenic acid?

At low-to-moderate dietary doses, CGA is generally well tolerated with no documented cytotoxicity in cell studies up to 30 μg/mL. The primary documented concern in humans is a moderate elevation of plasma homocysteine (approximately 12%) at 2 g/day, which may be relevant for individuals with cardiovascular risk; those taking antidiabetic medications should also exercise caution due to potential additive glucose-lowering effects, though formal interaction studies are currently absent from the literature.

### How does chlorogenic acid work as an antioxidant?

Chlorogenic acid acts through two complementary antioxidant mechanisms: it directly scavenges reactive oxygen species (ROS) and indirectly activates the Nrf2/ARE transcription pathway, upregulating endogenous antioxidant enzymes superoxide dismutase (SOD), catalase (CAT), and glutathione (GSH). In cell-based oxidative stress models, 150 μg/mL CGA increased SOD activity by 68.9%, CAT by 45.3%, and GSH by 39.7%, while reducing the lipid peroxidation marker malondialdehyde (MDA) by 32.4%, demonstrating potent enzymatic and non-enzymatic antioxidant activity.

### What is the difference between chlorogenic acid and caffeine in coffee?

Chlorogenic acid and caffeine are distinct compounds found together in coffee beans, but they have different chemical structures and mechanisms of action. While caffeine is a stimulant that affects the central nervous system, chlorogenic acid is a polyphenolic compound that functions primarily as an antioxidant and anti-inflammatory agent. Coffee naturally contains both compounds, but chlorogenic acid content can vary significantly depending on bean origin and roasting level, with lighter roasts retaining more CGA than darker roasts.

### How does chlorogenic acid compare to other polyphenol antioxidants like resveratrol or quercetin?

Chlorogenic acid, resveratrol, and quercetin are all polyphenolic antioxidants but differ in their molecular structure, dietary sources, and specific health mechanisms. While CGA primarily activates antioxidant enzyme expression (SOD, CAT, and GSH synthesis) and suppresses NF-κB/MAPK inflammatory pathways, resveratrol is known for sirtuin activation and quercetin for mast cell stabilization and anti-allergenic properties. CGA's strength lies in its ability to upregulate endogenous antioxidant defenses by up to 68.9% for SOD at physiologically relevant concentrations, making it uniquely effective for oxidative stress models.

### Who would benefit most from chlorogenic acid supplementation?

Individuals with elevated oxidative stress markers, chronic inflammatory conditions, or metabolic dysregulation—such as those with prediabetes or insulin resistance—may benefit most from chlorogenic acid supplementation. People with limited dietary intake of chlorogenic acid sources (coffee, tea, whole grains) and those seeking additional antioxidant support beyond diet alone are also good candidates. However, those with caffeine sensitivity should note that some chlorogenic acid supplements may contain residual caffeine, and individuals on blood thinners or with certain kidney conditions should consult a healthcare provider before supplementing.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*